Plain-English translation of NCT04530383 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether metformin, a widely used diabetes medication, can help people with cystic fibrosis-related diabetes who are already taking newer CF drugs called CFTR modulators. The researchers want to see if the medication can improve how your body handles blood sugar and support your overall health. You would take the medication at gradually increasing doses over several weeks, along with a vitamin B12 supplement to prevent a known side effect.
People with cystic fibrosis who take newer CF medications sometimes develop diabetes as a side effect, even though the CF drugs are helping their lungs. This trial exists to find out whether this medication could help manage that diabetes and potentially improve how the CF medications work in your body.
You likely qualify if…
You likely don't qualify if…
You would start taking the medication at a low dose (500 mg twice daily) for one week, then gradually increase it over two more weeks until you reach the full dose of 1000 mg twice daily, which you would continue for 14 weeks. Throughout the study, you would take a daily vitamin B12 supplement to prevent deficiency. You would have regular visits with the study team to check your blood sugar levels, monitor how you're tolerating the medication, and assess whether it's helping you.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Kansas Medical Center
Enrollment target
~30 participants
Started
February 2022
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Matthias A Salathe, M.D.
Professor
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.